Evidence map›Paper›PMID 40934935›Full record

SynthesisThe lancet. Diabetes & endocrinology2025

Global, regional, and national cascades of diabetes care, 2000-23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study.

Lauryn K Stafford, Anna Gage, Yvonne Yiru Xu, Madeleine Conrad, Ismael Barreras Beltran, Edward J Boyko, Bruce B Duncan, Simon I Hay, Hailey Lenox, Rafael Lozano and 8 more

Abstract readSystematic Review
In one paragraph

Synthesis in The lancet. Diabetes & endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Observational
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Glycemic response trajectories on metformin monotherapy in real-world diabetes care.medRxiv : the preprint server for health sciences · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lauryn K StaffordInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: laurynks@uw.edu.
Anna GageInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Yvonne Yiru XuInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Madeleine ConradInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Ismael Barreras BeltranInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Edward J BoykoSchool of Medicine, University of Washington, Seattle, WA, USA; General Medicine Service, Department of Veterans Affairs, Seattle WA, USA.
Bruce B DuncanPostgraduate Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Simon I HayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Hailey LenoxInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Rafael LozanoInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; Department of Public Health, School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Dianna J MaglianoSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Diabetes and Population Health Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Carlos A Aguilar SalinasDepartamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; All India Institute of Medical Sciences, Department of Endocrinology & Metabolism, Biotechnology Block, New Delhi, India.
Nikhil TandonInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Pedro ZitkoHealth Service & Population Research Department, IoPPN, King's College London, London, UK; Departamento de Salud Global, Escuela de Salud Pública, Universidad de Chile, Santiago, Chile.
Christopher J L MurrayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Theo VosInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Annie HaakenstadInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Kanyin Liane OngInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes is a serious global health challenge, with a rising prevalence and substantial effect on disability and mortality worldwide. Despite medical advancements, gaps in the cascade of diabetes care-comprising diagnosis, treatment, and glycaemic management-persist, hindering effective management. We aimed to comprehensively assess the state of the diabetes cascade of care globally, identifying areas of strength and needs for improvement in diabetes management.

methodsUsing data and methods from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), this modelling analysis spanned the years 2000 to 2023 and covered 204 countries and territories. We systematically reviewed cross-sectional surveys that are representative of the general population and the published and grey literature to estimate the proportion of people with diabetes who are undiagnosed, diagnosed but untreated, receiving treatment with suboptimal glycaemic concentrations, and receiving treatment with optimal glycaemic concentrations. Treatment was defined as current use of insulin or other hypoglycaemic medication. We separately modelled these quantities by location, year, age, and sex using DisMod-MR 2.1, a hierarchical Bayesian meta-regression modelling tool, then scaled the estimates so that they sum to 100% of people living with diabetes in each stratum. Using GBD 2023 estimates of the number of people with diabetes, we calculated the diabetes cascade of care: proportion of people diagnosed among those with diabetes, proportion of people receiving treatment among those with diagnosed diabetes, and proportion of people with optimal glycaemic concentrations among those receiving treatment for diabetes across all strata.

findingsIn 2023, an estimated 55·8% (95% UI 49·3-62·3) of people with diabetes aged 15 years and older were diagnosed with diabetes globally. The proportion of people with diagnosed diabetes who were on treatment was 91·4% (88·0-94·2), and the proportion of people on diabetes treatment with optimal glycaemic concentrations was 41·6% (35·7-48·5). Among all people with diabetes, the proportion with optimal glycaemic concentrations on treatment was 21·2% (17·4-25·6) in 2023 globally. Substantial regional differences were observed, with the highest rates of diagnosis in high-income North America, the highest rates of treatment among those with diagnosed diabetes in high-income Asia Pacific, and the highest rates of optimal glycaemic concentrations among those receiving treatment for diabetes in southern Latin America. Between 2000 and 2023, globally, the proportion of people diagnosed with diabetes increased by 8·3 (6·6-10·0) percentage points, and the proportion of people receiving treatment among those diagnosed increased by 7·2 (5·7-8·8) percentage points. The proportion of people receiving treatment who had optimal glycaemic concentrations increased by 1·3 (0·8-1·8) percentage points.

interpretationDespite improvements over the past two decades, underdiagnosis and suboptimal glycaemic management of diabetes remain major challenges globally, particularly in low-income and middle-income countries. These findings highlight the urgent need for enhanced strategies and capacity building to improve the detection, treatment, and management of diabetes worldwide. Targeted interventions to bolster health-care systems' capacity to effectively diagnose and manage diabetes could lead to better health outcomes and reduce the burden of this growing disease.

fundingBill & Melinda Gates Foundation.

Indexed as

Diabetes MellitusGlobal Burden of DiseaseCross-Sectional StudiesFemaleGlobal HealthHumansMale

Identifiers

PMID40934935
PMCPMC13537427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.